both dropped on heavy volume at the same time.
can exel not provide data until October
been holding acad since 2012 bought in the 2s with some more buying and selling in between. Acad will be huge IF Alzheimer drug succeeds coming end of year. We know it works for antipsychotic for Parkinson if/when they file for nda.
immu to me is momentum play on their lupus drug eprat for lupus, they had a catalyst end of June, but I read their partner is not releasing data for their lupus drug summer time. so it could linger, but the volume the last couple of days have been showing a possible run.